Malignancies in inflammatory bowel disease

Current Opinion in Gastroenterology

Volumn 19, Issue 4, 2003, Pages 366-370

  Srinivasan, Radhika ^a,b   Lewis, James D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b PENN PRESBYTERIAN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BIOLOGICAL MARKER; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADENOCARCINOMA; BILE DUCT CARCINOMA; BIOLOGY; CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RISK; CARCINOGENESIS; COLON CANCER; COLON RESECTION; COLONOSCOPY; COLORECTAL CANCER; CROHN DISEASE; DIGESTIVE SYSTEM CANCER; DRUG SAFETY; DYSPLASIA; ENTERITIS; GALLBLADDER CARCINOMA; HUMAN; ILEUM CANCER; ILEUM POUCH; INTESTINE ANASTOMOSIS; INTESTINE CANCER; LIVER CANCER; LIVER CELL CARCINOMA; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT TRANSFORMATION; MORTALITY; NONHODGKIN LYMPHOMA; PANCREAS CANCER; PROCTOCOLECTOMY; RECTUM CANCER; REVIEW; RISK FACTOR; SCLEROSING CHOLANGITIS; ULCERATIVE COLITIS;

EID: 0037999880     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-200307000-00007     Document Type: Review

References (30)

1. Lewis JD, Deren JJ, Lichtenstein GR: Cancer risk in patients with inflammatory bowel disease. Gastroenterol Clin N Am 1999, 28:459-477.
2. Befrits R, Ljung T, Jaramillo E, et al.: Low-grade dysplasia in extensive, long-standing inflammatory bowel disease: a follow-up study. Dis Colon Rectum 2002, 45:615-620. This Swedish study of 60 patients with IBD (49 CUC, 11 CD) and low-grade dysplasia appears to question the current recommendation of immediate colectomy when low-grade dysplasia is detected in flat colonic mucosa and confirmed by a second expert pathologist, because no cases of progression to high-grade dysplasia was evident in this study.
3. Bernstein C, Shanahan F, Weinstein W: Are we telling the truth about surveillance colonoscopy in ulcerative colitis? Lancet 1994, 343:71-74.
4. Ullman TA, Loftus EV, Kakar S, et al.: The fate of low grade dysplasia in ulcerative colitis. Am J Gastroenterol 2002, 97:922-927. This study of 18 patients with UC and low-grade dysplasia who were observed for a median of 32 months at a North American tertiary care center reported a cumulative incidence of 33% for progression to an advanced lesion at 5 years. This concurs with the current recommendation that total proctocolectomy should be offered to all patients with low-grade dysplasia in flat colonic mucosa. This study contradicts the findings of the study by Befrits et al. [2•].
5. Weedon DD, Shorter RG, Ilstrup DM, et al.: Crohn's disease and cancer. N Engl J Med 1973, 289:1099-1103.
6. Prior P, Gyde S, Cooke WT, et al.: Mortality in Crohn's disease. Gastroenterol 1981, 80:307-312.
7. Weterman IT, Biemond l, Pena AS: Mortality and causes of death in Crohn's disease. Review of 50 years experience in Leiden University hospital. Gut 1990, 31:1387-1390.
8. Persson PG, Bernell O, Leijonmarck CE, et al.: Survival and cause-specific mortality in inflammatory bowel disease: a population-based cohort study. Gastroenterology 1996, 110:1339-1345.
9. Loftus EV, Silverstein MD, Sandborn WJ, et al.: Crohn's disease in Olmstead County, Minnesota. 1940-1993: incidence, prevalence and survival. Gastroenterology 1998, 114:1161-1168.
10. Palli D, Trallori G, Saieva C, et al.: General and cancer specific mortality of a population based cohort of patients with inflammatory bowel disease: the Florence study. Gut 1998, 42:175-179.
11. Ekbom A, Helmick CG, Zack M, et al.: Survival and causes of death in patients with inflammatory bowel disease: a population-based study. Gastroenterology 1992, 103:954-960.
12. Jess T, Winther KV, Munkholm P, et al.: Mortality and causes of death in Crohn's disease: follow up of a population based cohort in Copenhagen County. Denmark. Gastroenterol 2002, 122:1808-1814. A population-based cohort study of 374 patients with CD, diagnosed between 1962 and 1987, who were observed until 1997 for mortality and causes of death. Seven patients died of cancer of the large or small intestine.
13. Laureti S, Ugolini F, D'Errico A, et al.: Adenocarcinoma below ileoanal anastomosis for ulcerative colitis. Dis Col Rectum 2002, 45:418-421. Case report of a 47-year-old patient with CUC in whom anal canal adenocarcinoma developed after a hand-sewn ileal pouch-anal anastomosis after a mucosectomy.
14. Botterill ID, Sagar PM: Adenocarcinoma in the residual outflow tract after incomplete excision of a failed ileoanal pouch: a late complication of unrecognized Crohn's colitis. Dis Colon Rectum 2002, 45:1112-1115. Case report of a 36-year-old patient with CD in whom an adenocarcinoma developed in the residual tract 12 years after the incomplete excision of a failed IPAA.
15. Baratsis S, Hadjidimitriou F, Christodoulou M, et al.: Adenocarcinoma in the anal canal after ileal pouch-anal anastomosis for ulcerative colitis using a double stapling technique: report of a case. Dis Colon Rectum 2002, 45:687-691. Case report of a 49-year-old patient with CUC who presented 2 years after an IPAA by a double stapling technique and received a diagnosis of adenocarcinoma of the anal canal.
16. Ravitch MM: The reception of new operations. Ann Surg 1984, 200:231-246.
17. Stern H, Walfish S, Mullen B, et al.: Cancer in an ileoanal reservoir: a new late complication? Gut 1990, 32:473-475.
18. Puthu D, Rajan N, Rao R, et al.: Carcinoma of the rectal pouch following restorative proctocolectomy: report of a case. Dis Col Rectum 1992, 35:257-260.
19. Rodriguez-Sanjuam JC, Polavieja MG, Naranjo A, et al.: Adenocarcinoma in an ileal pouch for ulcerative colitis. Dis Col Rectum 1995, 38:779-780.
20. Sequens R: Cancer of the anal canal (transitional zone) after restorative proctocolectomy with stapled ileal pouch-anal anastomosis. Int J Colorectal Dis 1997, 12:254-255.
21. Iwama T, Kamikawa J, Higuchi T, et al.: Development of invasive adenocarcinoma in a long-standing diverted ileal J-pouch for ulcerative colitis: report of a case. Dis Col Rectum 2000, 43:101-104.
22. Hulten L, Willen R, Nilsson O, et al.: Mucosal assessment for dysplasia and cancer in the ileal pouch mucosa in patients operated on for ulcerative colitis-a 30-year follow-up study. Dis Colon Rectum 2002, 45:448-452. Evaluation by two groups of pathologists of histologic specimens from 40 patients with Koch pouch after a mean follow-up of 30 years failed to reveal high-grade dysplasia or invasive carcinoma.
23. Fraser AG, Orchard TR, Robinson EM, et al.: Long term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther 2002, 16:1225-1232. A retrospective review of 626 patients who received azathioprine for a mean duration of 27 months. No increased risk of cancer was observed.
24. Dayharsh GA: Loftus EV, Sandborn WJ, et al. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology 2002, 122:72-77. Treatment of IBD with azathioprine or 6-mercaptopurine appears to pose a small increased risk of EBV-positive lymphoma. Five of 7 EBV-positive lymphomas and 1 of 11 EBV negative lymphomas occurred in patients treated with purine analogues.
25. Brown LS, Greene MH, Gershon SK, et al.: Tumor necrosis factor antagonist therapy and lymphoma development. Arthritis & Rheumatism 2002, 46:3151-3158. This report of 26 cases of lymphoma in patients receiving anti-TNF therapy that were reported to the FDA MedWatch postmarket adverse event surveillance system should prompt the initiation of additional studies to formally evaluate this association.
26. Soetikno RM: Lin OS, Heidenreich PA, et al. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002, 56:48-54. A metaanalysis of 11 published studies on the risk of colorectal neoplasia in patients with ulcerative colitis with and without PSC. An approximately four fold increased risk of CRC was evident in CUC patients with PSC.
27. Bergquist A, Ekbom A, Olsson R, et al.: Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002, 36:321-327. A Swedish study of 604 patients with PSC followed up for a median of 5.7 years showed a 13.3% frequency of hepatobiliary malignancies, which was 161 times that of the risk in the general population. The PSC cohort also had a 10-fold increased risk of CRC and a 14-fold increased risk of pancreatic cancer in comparison with the Swedish general population. This increased risk of pancreatic cancer is a novel finding.
28. Angulo P, Maor-Kendler Y, Lindor KD: Small-duct primary sclerosing cholangills: a long-term follow up study. Hepatology 2002, 35(6):1494-1500. A report on 18 small duct patients with PSC, a largely unstudied patient group, revealed a comparable survival data in comparison with the general population of the United States. Some patients with small duct PSC appear to progress to classic PSC. However, hepatobiliary malignancies did not develop in any of the patients with small duct PSC.
29. Buckles DC, Lindor KD, LaRusso NF, et al.: In primary sclerosing cholangitis, gallbladder polyps are frequently malignant. Am J Gastroenterol 2002, 97:1138-1142. A report on 14 of 102 patients with PSC who underwent cholecystectomy who had a gallbladder mass; 57% of the masses were malignant. Among the patients with benign masses, a third had associated epithelial cell dysplasia, whereas 57% of patients with primary gallbladder cancers had associated epithelial cell dysplasia. This suggests a dysplasia-carcinoma sequence. The authors recommend that cholecystectomy should be performed in all PSC patients with gallbladder polyps.
30. ARF, in the mucosa of patients with adenocarcinoma (50%), dysplasia (33%), and nonneoplastic (60%) CUC was greater than in normal control tissues (3.7%). This raises the intriguing possibility that this biomarker could be used in colonoscopic surveillance programs.